Translating Science

Transforming Lives

Extending life’s moments for children and adults living with rare diseases

Innovation, fueled by science and a passion for patients

PTC is an established global biopharmaceutical company that delivers transformative therapies for people living with rare diseases. For 25 years, we have been harnessing our scientific platforms to create new therapies that address the underlying cause of the disease and deliver on our promise to create more moments for those who count on us.

Explore our science

Focused research platforms at work for patients

Splicing

Modulating splicing to control protein production

Learn more

Inflammation & Ferroptosis

Targeting oxidative stress and inflammation pathways to treat CNS diseases

Learn more

Our Products

Challenging what's possible

Harnessing groundbreaking science for patients has led to many firsts – the first approved treatment for Duchenne in the world, the first approved gene therapy directly infused into the brain, and the first approved small molecule splicing modifier. Our innovative pipeline continues to expand as we discover and develop treatments using the newest technologies available.

See our products

Clinical Trials

We are committed to making progress in rare disease through clinical trial research.

Learn more about PTC's Clinical Trials

Medical research areas

Diseases in focus

Aromatic L-amino acid decarboxylase (AADC) deficiency

Patients with AADC deficiency lack dopamine, an essential neurotransmitter that controls movement

Duchenne muscular dystrophy (DMD)

Rare and fatal genetic disorder resulting in progressive muscle weakness from early childhood

Phenylketonuria (PKU)

Metabolic condition caused by mutations in PAH, a key digestive enzyme, that causes cognitive disabilities and seizures

See all therapeutic areas

Join Our Team

We love what we do

PTC employees are working to change patients’ lives every single day.

We are motivated by our patients and the drive for them to have more moments with their families, made possible in part by our research and therapies.
If you’re looking to take on rewarding work with inspiring colleagues, come grow with us.

View PTC careers

The Latest on PTC

Making headlines

See all Newsroom Articles See all Press Releases

PRESS RELEASE

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Today our leaders shared a corporate update and financial results for the fourth quarter ending December 31, 2024.

Read More
PRESS RELEASE

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will participate in fireside chats at two upcoming investor conferences in March.

Read More
PRESS RELEASE

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

The U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia (FA). The application has been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of Aug. 19, 2025.

Read More